Join the Semaglutide group to help and get support from people like you.
Semaglutide News
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 – Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...
'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy
TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...
Semaglutide Has Lasting Benefit for Weight Loss
TUESDAY, May 21, 2024 – Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual...
Semaglutide Reduces Need for Diuretics in Heart Failure
THURSDAY, May 16, 2024 – Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 – For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online...
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide
FRIDAY, April 12, 2024 – For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study
WEDNESDAY, April 10, 2024 – Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Diabetes, Type 2